The Edward P. Evans Center for Myelodysplastic Syndromes (MDS)
Our Mission
The mission of the Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at Columbia University is to foster an all-encompassing approach in studying MDS giving us molecular, cellular genetic and epigenetic insights to develop and test innovative therapies. We will map out how it arises and progresses during transformation to Acute Myeloid Leukemia (AML) by studying the generation and fate of MDS cells in their environment in the bone marrow and during aging. We will generate new epigenetic-based approaches, uncovering insights about MDS cells that will lead to new and more effective therapies. The Edward P. Evans Center for MDS will also develop a strong educational program to recruit and train junior and senior scientists with multidisciplinary expertise that can be leveraged to better understand MDS and develop new treatment options for patients.
We will capitalize on the wealth of the multidisciplinary expertise of the Columbia University Irving Medical Center (CUIMC) faculty in basic, translational and clinical research, our Longitudinal MDS Sample Repository of more than 60,000 samples from thousands of unique MDS patients studied longitudinally and technical Innovation developed by members of our team and others offered at CUIMC, Herbert Irving comprehensive cancer center (HICCC) and cores.
News
- September 12, 2023
Dr. Raza and Dr. Ali will focus on developing new strategies to target tumor macrophage hybrid cells in order to prevent cancer metastasis and overcome resistance to traditional cancer therapies.
Topic
- September 11, 2023
Four teams of researchers at Columbia University have been awarded 2023 Edward P. Evans Center for Myelodysplastic Syndromes (MDS) Pilot Awards and Fellowships
Topic
- November 10, 2022
In the last 50 years, the main approaches for treating myelodysplastic syndromes or acute myeloid leukemia have not changed. The Kousteni lab aims to change that.
